Malin Hultcrantz

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

MD PhD, Specialist i internmedicin och hematologi

Artiklar

Article: LEUKEMIA. 2021;35(2):476-484
Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients
Landtblom AR; Andersson TM-L; Dickman PW; Smedby KE; Eloranta S; Batyrbekova N; Samuelsson J; Bjorkholm M; Hultcrantz M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(5):904-907
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
Article: JOURNAL OF INTERNAL MEDICINE. 2020;287(4):448-454
Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden
Hultcrantz M; Landtblom AR; Andreasson B; Samuelsson J; Dickman PW; Kristinsson SY; Bjorkholm M; Andersson TM-L
Article: THROMBOSIS RESEARCH. 2020;186:86-92
Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors
Hultcrantz M; Modlitba A; Vasan SK; Sjolander A; Rostgaard K; Landgren O; Hjalgrim H; Ullum H; Erikstrup C; Kristinsson SY; Edgren G
Article: BLOOD CANCER JOURNAL. 2019;9(12):101
Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
Yellapantula V; Hultcrantz M; Rustad EH; Wasserman E; Londono D; Cimera R; Ciardiello A; Landau H; Akhlaghi T; Mailankody S; Patel M; Medina-Martinez JS; Ossa JEA; Levine MF; Bolli N; Maura F; Dogan A; Papaemmanuil E; Zhang Y; Landgren O
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2019;94(12):1364-1373
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
Rustad EH; Misund K; Bernard E; Coward E; Yellapantula VD; Hultcrantz M; Ho C; Kazandjian D; Korde N; Mailankody S; Keats JJ; Akhlaghi T; Viny AD; Mayman DJ; Carroll K; Patel M; Famulare CA; Op Bruinink DH; Hutt K; Jacobsen A; Huang Y; Miller JE; Maura F; Papaemmanuil E; Waage A; Arcila ME; Landgren O
Article: JAMA ONCOLOGY. 2019;5(9):1293-1301
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
Landgren O; Hofmann JN; McShane CM; Santo L; Hultcrantz M; Korde N; Mailankody S; Kazandjian D; Murata K; Thoren K; Ramanathan L; Dogan A; Rustad E; Lu SX; Akhlaghi T; Kristinsson SY; Bjorkholm M; Devlin S; Purdue MP; Pfeiffer RM; Turesson I
Article: BLOOD CANCER JOURNAL. 2019;9(2):15
Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.
Kazandjian D; Hill E; Hultcrantz M; Rustad EH; Yellapantula V; Akhlaghi T; Korde N; Mailankody S; Dew A; Papaemmanuil E; Maric I; Kwok M; Landgren O
Article: PLOS ONE. 2019;14(3):e0211600
Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.
Rustad EH; Hultcrantz M; Yellapantula VD; Akhlaghi T; Ho C; Arcila ME; Roshal M; Patel A; Chen D; Devlin SM; Jacobsen A; Huang Y; Miller JE; Papaemmanuil E; Landgren O
Article: LEUKEMIA. 2018;32(10):2203-2210
Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients
Landtblom AR; Bower H; Andersson TM-L; Dickman PW; Samuelsson J; Bjorkholm M; Kristinsson SY; Hultcrantz M
Article: JAMA ONCOLOGY. 2018;4(6):821-827
Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.
Landgren O; Zeig-Owens R; Giricz O; Goldfarb D; Murata K; Thoren K; Ramanathan L; Hultcrantz M; Dogan A; Nwankwo G; Steidl U; Pradhan K; Hall CB; Cohen HW; Jaber N; Schwartz T; Crowley L; Crane M; Irby S; Webber MP; Verma A; Prezant DJ
Article: ANNALS OF INTERNAL MEDICINE. 2018;168(5):317-325
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms A Population-Based Cohort Study
Hultcrantz M; Bjorkholm M; Dickman PW; Landgren O; Derolf AR; Kristinsson SY; Andersson TML
Article: BLOOD ADVANCES. 2017;1(25):2392-2398
The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study
Jonsdottir G; Lund SH; Bjorkholm M; Turesson I; Hultcrantz M; Porwit A; Jethava YS; Landgren O; Kristinsson SY
Article: BLOOD CANCER JOURNAL. 2017;7(10):e618
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.
Landgren O; Graubard BI; Kumar S; Kyle RA; Katzmann JA; Murata K; Costello R; Dispenzieri A; Caporaso N; Mailankody S; Korde N; Hultcrantz M; Therneau TM; Larson DR; Cerhan JR; Rajkumar SV
Article: BLOOD ADVANCES. 2017;1(22):1911-1918
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma
Mailankody S; Kazandjian D; Korde N; Roschewski M; Manasanch E; Bhutani M; Tageja N; Kwok M; Zhang Y; Zingone A; Lamy L; Costello R; Morrison C; Hultcrantz M; Christofferson A; Washington M; Boateng M; Steinberg SM; Stetler-Stevenson M; Figg WD; Papaemmanuil E; Wilson WH; Keats JJ; Landgren O
Article: OBESITY. 2017;25(8):1317-1320
Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease.
Hofmann JN; Mailankody S; Korde N; Wang Y; Tageja N; Costello R; Zingone A; Hultcrantz M; Pollak MN; Purdue MP; Landgren O
Article: ANNALS OF HEMATOLOGY. 2017;96(2):261-269
History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study
Lindqvist EK; Landgren O; Lund SH; Turesson I; Hultcrantz M; Goldin L; Bjorkholm M; Kristinsson SY
Article: TRANSFUSION. 2016;56(6):1622-1627
Blood donation and risk of polycythemia vera
Edgren G; Nyren O; Hultcrantz M; Nielsen KR; Pedersen OBV; Bjorkholm M; Rostgaard K; Hjalgrim H
Article: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(20):2288-2295
Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study
Hultcrantz M; Wilkes SR; Kristinsson SY; Andersson TM-L; Derolf AR; Eloranta S; Samuelsson J; Landgren O; Dickman PW; Lambert PC; Bjorkholm M
Article: HAEMATOLOGICA. 2015;100(1):107-113
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Blimark C; Holmberg E; Mellqvist U-H; Landgren O; Bjoekholm M; Hultcrantz M; Kjellander C; Turesson I; Kristinsson SY
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2014;12(11):1816-1821
Elevated risk of venous but not arterial thrombosis in Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma
Hultcrantz M; Pfeiffer RM; Bjorkholm M; Goldin LR; Turesson I; Schulman S; Landgren O; Kristinsson SY
Article: ANNALS OF HEMATOLOGY. 2014;93(9):1491-1498
Self-reported fertility in long-term survivors of acute myeloid leukemia
Branvall E; Derolf AR; Johansson E; Hultcrantz M; Bergmark K; Bjorkholm M
Article: BEST PRACTICE AND RESEARCH: CLINICAL HAEMATOLOGY. 2014;27(2):141-153
Leukemic transformation in myeloproliferative neoplasms: Therapy-related or unrelated?
Bjorkholm M; Hultcrantz M; Derolf AR
Article: LEUKEMIA AND LYMPHOMA. 2013;54(10):2226-2230
Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms
Abelsson J; Andreasson B; Samuelsson J; Hultcrantz M; Ejerblad E; Johansson B; Emanuel R; Mesa R; Johansson P
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(24):2995-3001
Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
Hultcrantz M; Kristinsson SY; Andersson TM-L; Landgren O; Eloranta S; Derolf AR; Dickman PW; Bjorkholm M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(21):2897-2903
Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes
Kristinsson SY; Bjorkholm M; Hultcrantz M; Derolf AR; Landgren O; Goldin LR
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(18):2514-2520
Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008
Bjorkholm M; Ohm L; Eloranta S; Derolf A; Hultcrantz M; Sjoberg J; Andersson T; Hoglund M; Richter J; Landgren O; Kristinsson SY; Dickman PW
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(17):2410-2415
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
Bjorkholm M; Derolf AR; Hultcrantz M; Kristinsson SY; Ekstrand C; Goldin LR; Andreasson B; Birgegard G; Linder O; Malm C; Markevarn B; Nilsson L; Samuelsson J; Granath F; Landgren O
Visa fler

Alla övriga publikationer

Review: JAMA ONCOLOGY. 2020;6(3):425-432
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
Maura F; Bolli N; Rustad EH; Hultcrantz M; Munshi N; Landgren O
Review: BEST PRACTICE AND RESEARCH: CLINICAL HAEMATOLOGY. 2020;33(1):101153
Genomic profiling of multiple myeloma: New insights and modern technologies.
Hultcrantz M; Yellapantula V; Rustad EH
Letter: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2020;20(3):198-200
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Salcedo M; Lendvai N; Mastey D; Schlossman J; Hultcrantz M; Korde N; Mailankody S; Lesokhin A; Hassoun H; Smith E; Shah U; Diab V; Werner K; Landau H; Lahoud O; Drullinsky P; Shah G; Chung D; Scordo M; Giralt S; Landgren O
Corrigendum: BLOOD CANCER JOURNAL. 2020;10(1):11
Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.
Yellapantula V; Hultcrantz M; Rustad EH; Wasserman E; Londono D; Cimera R; Ciardiello A; Landau H; Akhlaghi T; Mailankody S; Patel M; Medina-Martinez JS; Ossa JEA; Levine MF; Bolli N; Maura F; Dogan A; Papaemmanuil E; Zhang Y; Landgren O
Meeting abstract: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19(10):e298-e299
Depth of Response and Outcomes by Initial Therapy Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Shah G; Chung D; Scordo M; Seier K; Hassoun H; Hultcrantz M; Korde N; Lesokhin A; Mailankody S; Shah U; Smith E; Mezzi K; Welliver T; Braunlin M; Werther W; Delgado R; Bashir Q; Srour S; Landgren CO; Landau H; Qazilbash M; Giralt S
Meeting abstract: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19(10):E219
Multiple myeloma and comorbidity: a population-based study
Sverrisdottir I; Rognvaldsson S; Turesson I; Hultcrantz M; Bjorkholm M; Landgren CO; Kristinsson S
Meeting abstract: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19(10):e142-e143
Practice Patterns with Focal Progression on Daratumumab Therapy
Bal S; Peterson T; Landau H; Chung D; Giralt S; Korde N; Mailankody S; Smith E; Shah U; Hultcrantz M; Hassoun H; Landgren CO; Lesokhin A
Meeting abstract: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19(10):e46
Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma
Bal S; Landau H; Shah G; Scordo M; Dahi P; Lahoud O; Hassoun H; Hultcrantz M; Korde N; Lesokhin A; Lendvai N; Mailankody S; Landgren CO; Smith E; Giralt S; Chung D
Meeting abstract: BLOOD. 2018;132:3184
Capture Rate of the Adaptive Next Generation Sequencing VDJ Assay in Multiple Myeloma
Hultcrantz M; Rustad EH; Yellapantula V; Akhlaghi T; Jacob A; Patel A; Korde N; Mailankody S; Lendvai N; Lesokhin AM; Hassoun H; Smith EL; Lahoud OB; Landau HJ; Shah GL; Scordo M; Chung DJ; Giralt S; Papaemmanuil E; Landgren O
Meeting abstract: BLOOD. 2018;132:4437
Risk Factors for Acute Myeloid Leukemia and Myelodysplastic Syndromes in Patients with Multiple Myeloma: An Updated Analysis
Jonsdottir G; Bjorkholm M; Turesson I; Hultcrantz M; Porwit A; Jethava Y; Landgren O; Kristinsson SY
Meeting abstract: BLOOD. 2018;132:5588
Mytype: A Capture Based Sequencing Approach to Detect Somatic Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma
Yellapantula V; Hultcrantz M; Rustad EH; Landau HJ; Iacobuzio-Donahue C; Akhlaghi T; Amit I; Ledergor G; Korde N; Mailankody S; Kazandjian D; Patel A; Bolli N; Papaemmanuil E; Landgren O
Meeting abstract: BLOOD. 2018;132:959
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial
Mailankody S; Ghosh A; Staehr M; Purdon TJ; Roshal M; Halton E; Diamonte C; Pineda J; Anant P; Bernal Y; Wills A; Korde N; Lendvai N; Lesokhin AM; Hassoun H; Hultcrantz M; Landau HJ; Shah GL; Scordo M; Chung DJ; Lahoud OB; Khattar P; de larrea CF; Gao Q; Jungbluth A; Park JH; Curran KJ; Sauter CS; Palomba ML; Senechal B; Wang X; Dogan A; Giralt S; Riviere I; Landgren O; Brentjens RJ; Smith EL
Meeting abstract: BLOOD. 2018;132:3169
Whole Genome Sequencing of Extramedullary Myeloma Autopsy Tumors Reveals a Genomic Portrait at Culmination of Clonal Convergence
Yellapantula VD; Rustad EH; Glozdik D; Gundem G; Fan J; Medina J; Patel A; Patel M; Hultcrantz M; Peled JU; Lendvai N; Landgren O; Giralt S; Iacobuzio-Donahue C; Papaemmanuil E; Landau HJ; Lesokhin AM
Meeting abstract: BLOOD. 2018;132:1983
MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m²) in Combination with Lenalidomide and Dexamethasone
Korde N; Mastey D; Mailankody S; Hassoun H; Lesokhin AM; Smith EL; Lendvai N; Hultcrantz M; Tavitian E; Salcedo M; Sams A; Diab V; Chung DJ; Scordo M; Lahoud OB; Landau HJ; Arcila ME; Giralt S; Ho C; Roshal M; Devlin SM; Dogan A; Landgren O
Meeting abstract: BLOOD. 2018;132:4751
Continuous Mobile Wearable Bio-Monitoring of Newly Diagnosed Multiple Myeloma Patients Undergoing Initial Chemotherapy
Tavitian E; Mastey D; Salcedo M; Zarski A; Chansakul A; Diab V; Mailankody S; Hassoun H; Lesokhin AM; Lendvai N; Smith EL; Hultcrantz M; Sams A; Davis M; Davis E; Puklin S; Steinberger A; Shah GL; Landgren O; Atkinson T; Lengfellner J; Korde N
Meeting abstract: BLOOD. 2018;132:4619
Depth of Response and Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Shah GL; Seier K; Devlin SM; Chung DJ; Scordo M; Hultcrantz M; Korde N; Lendvai N; Lesokhin AM; Mailankody S; Smith EL; Landgren O; Landau HJ; Giralt S
Meeting abstract: BLOOD. 2018;132:4475
Next-Generation Sequencing-Based Assay Shows High Clonal Characterization Success Rate for Plasma Cell Neoplasms, and Concordance with Flow Cytometry in Minimal Residual Disease Detection
Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao JJ; Yu W; Maciag L; Benayed R; Hultcrantz M; Dogan A; Nafa K; Landgren O; Arcila ME
Meeting abstract: BLOOD. 2018;132:4444
V(D)J Sequence Capture for DNA-Based Minimal Residual Disease Detection in Multiple Myeloma
Rustad EH; Hultcrantz M; Yellapantula VD; Akhlaghi T; Ho C; Arcila ME; Roshal M; Patel A; Devlin SM; Jacobsen A; Huang Y; Miller JE; Papaemmanuil E; Landgren O
Meeting abstract: BLOOD. 2018;132:5591
Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience
Pianko MJ; Tiutan T; Flynn J; Devlin SM; Jaffer-Sathick I; Rossi AC; Salvatore SP; Landau HJ; Lendvai N; Smith EL; Korde N; Mailankody S; Lesokhin AM; Hultcrantz M; Chung DJ; Giralt S; Landgren O; Hassoun H
Letter: HAEMATOLOGICA. 2018;103(9):e412-e415
Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
Thorsteinsdottir S; Dickman PW; Landgren O; Blimark C; Hultcrantz M; Turesson I; Bjorkholm M; Kristinsson SY
Letter: ANNALS OF INTERNAL MEDICINE. 2018;169(4):268
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms RESPONSE
Hultcrantz M; Bjorkholm M; Landgren O; Kristinsson SY; Andersson TML
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):8036
Molecular underpinnings of clinical disparity patterns in African American (AA) versus Caucasian American (CA) multiple myeloma (MM) patients.
Hill EM; Kwok M; Yellapantula V; Hultcrantz M; Korde N; Mailankody S; Papaemmanuil E; Maric I; Kazandjian DG; Landgren O
Review: SEMINARS IN HEMATOLOGY. 2018;55(1):44-50
MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.
Landgren O; Lu SX; Hultcrantz M
Meeting abstract: BLOOD. 2016;128(22):3274
Longitudinal ¹⁸f-FDG-PET-CT Analysis in Newly Diagnosed Multiple Myeloma (NDMM) Patients Following Carfilzomib, Lenalidomide, Dexamethasone Induction and Lenalidomide Maintenance (CRd-R)
Korde NS; Kazandjian D; Roschewski M; Mailankody S; Hultcrantz M; Yuan CM; Stetler-Stevenson M; Choyke P; Hassoun H; Lesokhin AM; Lendvai N; Smith EL; Landgren O; Kurdziel KA; Lindenberg ML
Meeting abstract: BLOOD. 2016;128(22):3246
The Impact of Prior Malignancies on Second Malignancies and Survival in MM Patients: A Population-Based Study
Jonsdottir G; Lund SH; Bjorkholm M; Turesson I; Wahlin A; Hultcrantz M; Porwit A; Landgren O; Kristinsson SY
Meeting abstract: BLOOD. 2016;128(22):5650
Risk of Progression in Monoclonal Gammopathy of Undetermined Significance (MGUS): Results from a Population-Based Screening Study
Lindqvist EK; Lund SH; Costello R; Burton D; Korde NS; Mailankody S; Bjorkholm M; Eiriksdottir G; Launer LJ; Harris TB; Hultcrantz M; Gudnason V; Landgren O; Kristinsson SY
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):8003
Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients.
Mailankody S; Korde N; Roschewski MJ; Christofferson A; Boateng M; Zhang Y; Manasanch EE; Kazandjian DG; Kwok M; Bhutani M; Tageja N; Zingone A; Costello R; Lamy L; Hultcrantz M; Papaemmanuil E; Stetler-Stevenson M; Figg WD; Keats JJ; Landgren O
Letter: HAEMATOLOGICA. 2016;101(4):e145-e148
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study
Jonsdottir G; Lund SH; Bjorkholm M; Turesson I; Wahlin A; Mailankody S; Blimark C; Hultcrantz M; Porwit A; Landgren O; Kristinsson SY
Letter: HAEMATOLOGICA. 2015;100(10):e402-e405
Dysregulation of shelterin factors coupled with telomere shortening in Philadelphia chromosome negative myeloproliferative neoplasms
Dahlstrom J; Zhang X; Ghaderi M; Hultcrantz M; Bjorkholm M; Xu D
Letter: BLOOD. 2015;125(23):3665-3666
Survival in patients with familial and sporadic myeloproliferative neoplasms
Hultcrantz M; Lund SH; Landgren O; Samuelsson J; Goldin LR; Oddsson A; Bjorkholm M; Kristinsson SY
Review: CANCER MEDICINE. 2015;4(1):147-154
Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy
Hultcrantz M; Svensson T; Derolf AR; Kristinsson SY; Lindqvist EK; Ekbom A; Granath F; Bjorkholm M
Meeting abstract: BLOOD. 2014;124(21):632
Risk of Arterial and Venous Thrombosis in 11,155 Patients with Myeloproliferative Neoplasms and 44,620 Matched Controls; A Population-Based Study
Hultcrantz M; Andersson TM-L; Landgren O; Derolf AR; Dickman PW; Bjorkholm M; Kristinsson SY
Thesis / dissertation: 2013
Clinical and epidemiological studies in myeloproliferative neoplasms
Hultcrantz, Malin
Review: LAKARTIDNINGEN. 2012;109(51-52):2354-2357
[High hemoglobin, not always polycythaemia vera. Weak evidence for the effect of venesection in other erythrocytoses].
Hultcrantz M; Admasie J; Beshara S; Landin B; Palmblad J
Meeting abstract: BLOOD. 2012;120(21):945
Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients
Blimark C; Mellqvist U-H; Landgren O; Bjorkholm M; Hultcrantz ML; Kjellander C; Turesson I; Holmberg E; Kristinsson SY
Meeting abstract: BLOOD. 2012;120(21):1603
Elevated Risk of Venous but Not Arterial Thrombosis in Waldenstrm's Macroglobulinemia and Lymphoplasmacytic Lymphoma
Hultcrantz ML; Pfeiffer RM; Bjorkholm M; Goldin L; Turesson I; Schulman S; Landgren O; Kristinsson SY
Letter: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2012;10(5):962-964
Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based study
Kristinsson SY; Goldin L; Turesson I; Hultcrantz M; Bjorkholm M; Landgren O
Meeting abstract: BLOOD. 2010;116(21):1266-1267
Patterns of Survival and Causes of Death In 9,384 Patients with Myeloproliferative Neoplasms Diagnosed In Sweden Between 1973 and 2008
Hultcrantz M; Kristinsson SY; Andersson TM-L; Eloranta S; Derolf AR; Landgren O; Dickman PW; Bjorkholm M
Letter: ANNALS OF ONCOLOGY. 2007;18(6):1122-1123
Suicide in multiple myeloma and acute myeloid leukaemia
Bjorkholm M; Hultcrantz M; Kristinsson S; Brandt L; Ekbom A; Derolf A
Visa fler

Anställningar

Anknuten till Forskning, Medicin, Solna, Karolinska Institutet, 2023-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2013
Läkarexamen, Karolinska Institutet, 2006

Handledare

Nurgul Betyrbekova, Modeling multiple time-scales with flexible parametric survival models – with applications to Myeloproliferative Neoplasm (MPN), 2019

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Handledare

Nyheter från KI

Kalenderhändelser från KI